

May 30, 2025

The Manager – Listing

**BSE Limited**

1<sup>st</sup> Floor, New Trading Ring

Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai 400001

The Manager – Listing

**National Stock Exchange of India Ltd.**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block

Bandra-Kurla Complex, Bandra (E),

Mumbai 400051

Dear Sir(s),

**Sub: Press Release**

**Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN**

Please find enclosed the press release for the audited financial results for the financial year ended March 31, 2025.

Thanking you,

**For AstraZeneca Pharma India Limited**

**Manasa. R**

**Company Secretary**

**CORPORATE & REGD. OFFICE**  
**AstraZeneca Pharma India Ltd.**  
P. B. No. 4525, Block N1, 12th Floor,  
Manyata Embassy Business Park,  
Rachenahalli, Outer Ring Road,  
Bangalore - 560 045, INDIA

**TEL** : +91 80 6774 8000  
**FAX** : +91 80 6774 8857  
**CIN** : L24231KA1979PLC003563  
**WEB** : [www.astrazeneca.com/india](http://www.astrazeneca.com/india)

**FACTORY**  
12th Mile on Bellary Road  
Venkatala, Kattigenahalli Village  
Yelahanka  
Bangalore - 560 063  
INDIA

**TEL** : +91 80 6774 9000  
**FAX** : +91 80 2846 2208  
+91 80 6774 9628

## AstraZeneca Pharma India Limited marks a consistent 32 % growth as the company announces its annual results for FY 2024-25

Total Revenue from operations is INR 17162.9 Mn - up by 32% and Core EPS announced as INR 46.30

**Bengaluru, May 30, 2025:** AstraZeneca Pharma India Limited (the Company), a science-led biopharmaceutical company, today announced its full year performance for the financial year April 2024-March 2025. The Company sustained its momentum from previous quarters and recorded a significant year-on-year growth across therapeutic areas, achieving a 32% increase in revenue compared to the same period last year.

### Financial performance Summary -

| Summary                                |  | Q4 Jan'24-Mar'24<br>(Value in INR Mn) | Full year Apr'23-Mar'24 | Q4 Jan'25 – Mar'25<br>(Value in INR Mn) | Full year Apr'24-Mar'25 |
|--|--|---------------------------------------|-------------------------|---|-------------------------|
| Total Revenue from Operation           |  | 3832.0                                | 12955.3                 | 4804.8                                  | 17162.9                 |
| Profit before exceptional item and tax |  | 543.6                                 | 2031.1                  | 841.5                                   | 2531.5                  |
| Profit after exceptional item and tax  |  | 394.8                                 | 1615.1                  | 582.5                                   | 1157.4                  |
| TA wise performance                    | Oncology                               | 2399.6                                | 7510.9                  | 3158.5                                  | 11171.4                 |
|  | Biopharmaceuticals (CVRM, R&I and V&I) | 1204.6                                | 4537.0                  | 1227.4                                  | 4881.2                  |
|  | Rare Disease                           | 1.7                                   | 8.5                     | 20.0                                    | 31.7                    |

**Bhavana Agrawal, Chief Financial Officer & Director of the Company,** said, "FY 2024-25 marked significant progress for AstraZeneca Pharma India Limited, driven by strong growth of 32%. This reflects our strategic focus on science, specialist, and the strength of our innovation-led portfolio. As we scale impact across therapy areas, we remain committed to delivering sustainable value to the people, society and the planet."

**Dr. Sanjeev Panchal, Country President & Managing Director of the Company,** said, "Our company delivered a strong growth in Financial Year 2024-25 by bringing innovative medicine launches in India, giving us a momentum into 2025 and beyond. We are pleased to share that our company has for the first time crossed the INR 1700 cr mark (\$200 Mn). Science is sustaining and growing the success of our company, helping us transform the future of healthcare, and the health of people, society and the planet."

## Key milestones:

- Since 2023, the Company has delivered 14 approvals across its portfolio- Oncology, Biopharmaceutical, Rare Disease.
- In FY '24- '25 the company announced regulatory approvals for:
  - **Palivizumab (50mg/0.5mL):** Following the receipt of approval from Drugs Controller General of India (DCGI) in September 2023, the Company launched Palivizumab (50mg/0.5ml) in October 2024. This monoclonal antibody is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk paediatric patients.
  - **Tremelimumab (25mg/mL):** Following DCGI approval in May 2023, the company launched Tremelimumab in October 2024. Tremelimumab in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC).
  - **Durvalumab – Additional Indication (NSCLC):** Secured Central Drugs Standard Control Organization's (CDSCO) approval in September 2024 for an additional indication—neoadjuvant and adjuvant use in resectable NSCLC (tumors  $\geq 4$  cm and/or node-positive), in combination with chemotherapy and as monotherapy post-surgery.
  - **Olaparib + Durvalumab (Endometrial Cancer):** Received CDSCO approval for the additional indication for the maintenance treatment of adult patients with advanced or recurrent endometrial cancer who have not progressed following first-line treatment with Durvalumab in combination with platinum-based chemotherapy.
  - **Budesonide/Glycopyrronium/Formoterol:** Approved by CDSCO in December 2023 and launched in January 2025, this is indicated for maintenance treatment in adults with chronic obstructive pulmonary disease (COPD) to relieve symptoms and prevent exacerbations.
  - **Eculizumab (300mg/30mL):** Approved for import and distribution by CDSCO, this is indicated for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) to inhibit complement – mediated thrombotic microangiopathy.
  - **Durvalumab – Additional Indication:** Gained CDSCO approval in March 2025 for use of Durvalumab in combination with Tremelimumab for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
  - **Sodium Zirconium Cyclosilicate (5g/10g):** Received CDSCO permission for import and sale in March 2025. This novel oral suspension significantly improves hyperkalaemia management in adults, commonly associated with cardiovascular, renal, and metabolic conditions.
  - **Durvalumab: Additional Indication:** Gained CDSCO approval in March 2025 for use of Durvalumab for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
- **Partnership for Health System Sustainability and Resilience (PHSSR)** commissioned independent report was presented at the Embassy of Sweden in the presence of key dignitaries from the Ministry of Health & Family Welfare, key influencers from the healthcare ecosystem followed by a deep deliberation on how private and public sectors need to jointly prioritise areas of concern that emerged from the COVID-19 pandemic and prepare the Indian health system to tackle crises when needed.

## Key Appointments

- **Ms. Monica Widhani** was appointed as an Independent Director on the Board of the Company, with effect from September 25, 2024
- **Ms. Shilpa Divekar Nirula**, Independent Director has been unanimously elected as Chairperson of the Board, effective September 30, 2024
- **Mr. Jesus Javier Diaz Ropero Esteso** was appointed as a Non-Executive Director of the Company with effect from November 13, 2024
- **Ms. Shikha Mirchandani Chatrath** was appointed as Director – Commercial Excellence, BD & Strategy with effect from June 17, 2024
- **Mr. Srikanth. B.S.** was appointed as the Site-Lead, India Operations with effect from August 1, 2024

- **Ms Amita Bhave** was appointed as Head Regulatory Affairs at the Company with effect from November 18, 2024
- **Dr. Sandeep Arora** was appointed as Director, Medical Affairs with effect from March 3, 2025
- **Harish Dash** was appointed as Senior Director, Commercial IT & Digital with effect from March 3, 2025.

#### Recognitions:

- The Company was **recognised for a valuable contribution** in spreading **large scale awareness on RSV** in the country at National Neonatology Forum Program - NEOCON 2024
- The Company was awarded a **'Great Place To Work' for the seventh consecutive time**
- The Company was awarded **'ET Now Progressive Company of the year'** for demonstrating an exceptional commitment to workplace excellence and contributing significantly to industry success.
- Recognized as one of **'India's Best Organizations in Innovation' by ET Now**
- Awarded **'Pharma InHouse Legal Team of the Year'** at the 13th Annual Legal Era - Indian Legal Awards 2023-24
- Amarpreet Kaur Ahuja, Country HR Director, was featured among **"The Powerhouses of Indian HR: Women Driving Change and Innovation"** by Indian Conventions
- **Diversity and Inclusion Award 2024** at the 57th OPPI Annual Day
- Awarded **'Silver' for Best Employer for Women in Small Category** at the ASSOCHAM 5th Diversity & Inclusion Excellence Awards & Conclave – 2024

#### About AstraZeneca Pharma India Ltd

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Completing its 45 years in India, AstraZeneca Pharma India Limited is headquartered at Bengaluru, Karnataka in India and has a workforce of over 600 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: <https://www.astrazeneca.in/> or follow us on LinkedIn: [AstraZeneca India](#).